AU2005288689B2 - Methods and compositions relating to Alzheimer's disease - Google Patents

Methods and compositions relating to Alzheimer's disease Download PDF

Info

Publication number
AU2005288689B2
AU2005288689B2 AU2005288689A AU2005288689A AU2005288689B2 AU 2005288689 B2 AU2005288689 B2 AU 2005288689B2 AU 2005288689 A AU2005288689 A AU 2005288689A AU 2005288689 A AU2005288689 A AU 2005288689A AU 2005288689 B2 AU2005288689 B2 AU 2005288689B2
Authority
AU
Australia
Prior art keywords
alzheimer
protein
disease
proteins
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005288689A
Other languages
English (en)
Other versions
AU2005288689A1 (en
Inventor
Christian Baumann
Helen Byers
Abdul Hye
Richard Joubert
Stefan Kienle
Karsten Kuhn
Simon Lovestone
Stephen Lynham
Petra Prefot
Thorsten Prinz
Juergen Schaefer
Malcolm Ward
Jules Westbrook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Proteome Sciences PLC
Original Assignee
Kings College London
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, Proteome Sciences PLC filed Critical Kings College London
Publication of AU2005288689A1 publication Critical patent/AU2005288689A1/en
Application granted granted Critical
Publication of AU2005288689B2 publication Critical patent/AU2005288689B2/en
Priority to AU2011253636A priority Critical patent/AU2011253636B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AU2005288689A 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer's disease Expired AU2005288689B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011253636A AU2011253636B2 (en) 2004-09-29 2011-11-23 Methods and compositions relating to alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421639.6 2004-09-29
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011253636A Division AU2011253636B2 (en) 2004-09-29 2011-11-23 Methods and compositions relating to alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2005288689A1 AU2005288689A1 (en) 2006-04-06
AU2005288689B2 true AU2005288689B2 (en) 2011-10-27

Family

ID=33397455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005288689A Expired AU2005288689B2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer's disease

Country Status (10)

Country Link
US (2) US7897361B2 (cg-RX-API-DMAC7.html)
EP (3) EP2562545A1 (cg-RX-API-DMAC7.html)
JP (3) JP5483816B2 (cg-RX-API-DMAC7.html)
AT (1) ATE495445T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005288689B2 (cg-RX-API-DMAC7.html)
CA (1) CA2580532C (cg-RX-API-DMAC7.html)
DE (1) DE602005025897D1 (cg-RX-API-DMAC7.html)
DK (1) DK2354795T3 (cg-RX-API-DMAC7.html)
GB (1) GB0421639D0 (cg-RX-API-DMAC7.html)
WO (1) WO2006035237A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AU2009295357A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
JP5755149B2 (ja) * 2009-01-26 2015-07-29 エレクトロフォレティクス リミテッドＥｌｅｃｔｒｏｐｈｏｒｅｔｉｃｓ Ｌｉｍｉｔｅｄ 方法
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
CA2709621A1 (en) * 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
RU2627163C2 (ru) 2009-11-24 2017-08-03 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP6012923B2 (ja) 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
HK1201328A1 (en) * 2011-11-18 2015-08-28 Alnylam Pharmaceuticals, Inc. Quantification of transthyretin and its isoforms
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
JP2015520123A (ja) 2012-03-29 2015-07-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 個々のタンパク質バリアントに選択的な試薬を調製するナノスケールの方法
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP3255435A1 (en) 2012-04-13 2017-12-13 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2014040042A2 (en) 2012-09-10 2014-03-13 The Johns Hopkins University Diagnostic assay for alzheimer's disease
US9891108B2 (en) 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
JP6416793B2 (ja) * 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
GB201310203D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
EP3039431A4 (en) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
EP3092494A4 (en) * 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
WO2016160594A1 (en) * 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2019013341A1 (ja) * 2017-07-14 2019-01-17 株式会社島津製作所 疾患検出方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用
CA3268498A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020174447A1 (en) * 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) * 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
EP1572932A4 (en) * 2002-07-03 2008-05-14 Univ Illinois REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING THE EXPRESSION OF TUMOR GENE SCENARIAS
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020174447A1 (en) * 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Andreasen, N. et al., Arch Neurol. 1999, Vol.56, pages 673-680 *
Kanai, M. et al., Annals of Neurology, 1998, Vol.44, No.1, pages 17-26 *
Tilleman, K. et al., Proteomics, 2002, Vol.2, pages 94-104 *

Also Published As

Publication number Publication date
JP5483816B2 (ja) 2014-05-07
CA2580532A1 (en) 2006-04-06
AU2005288689A1 (en) 2006-04-06
JP2008514946A (ja) 2008-05-08
EP1794594A2 (en) 2007-06-13
US7897361B2 (en) 2011-03-01
JP2014209132A (ja) 2014-11-06
GB0421639D0 (en) 2004-10-27
ATE495445T1 (de) 2011-01-15
DE602005025897D1 (de) 2011-02-24
EP2562545A1 (en) 2013-02-27
EP2354795B1 (en) 2014-12-17
DK2354795T3 (en) 2015-02-16
EP2354795A1 (en) 2011-08-10
US20080070995A1 (en) 2008-03-20
WO2006035237A2 (en) 2006-04-06
WO2006035237A3 (en) 2006-08-03
JP5893269B2 (ja) 2016-03-23
JP2011209291A (ja) 2011-10-20
CA2580532C (en) 2019-06-25
US20110165146A1 (en) 2011-07-07
EP1794594B1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
AU2005288689B2 (en) Methods and compositions relating to Alzheimer's disease
EP3080609B1 (en) Biomarkers and methods relating to alzheimer's disease
Zetterberg Blood-based biomarkers for Alzheimer’s disease—An update
JP6954839B2 (ja) アルツハイマー病の診断及び治療のための材料及び方法
Hampel et al. Core biological marker candidates of Alzheimer’s disease–perspectives for diagnosis, prediction of outcome and reflection of biological activity
EP2569446B1 (en) Diagnostic markers for neuropsychiatric diseasen
US12419871B2 (en) Biomolecules involved in Alzheimer's disease
Ghidoni et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and the future
AU2005276238B2 (en) Methods and compositions relating to Alzheimer's disease
KR20130009205A (ko) 당뇨망막병증 진단용 마커 및 이의 용도
KR102547505B1 (ko) 주요 우울 장애 치료 효과 조기 예측용 바이오마커
AU2011253636B2 (en) Methods and compositions relating to alzheimer's disease
Blennow Development of Fluid Biomarkers for Alzheimer’s Disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired